morpholinoanthracycline mx2 has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arita, N; Hayakawa, T; Kuratsu, J; Kurisu, K; Uozumi, T; Ushio, Y | 1 |
| Bartlett, J; Basser, RL; Byrne, M; Cher, L; Clarke, K; Dalley, D; Findlay, M; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Mitchell, P; Pell, M; Underhill, C | 1 |
2 trial(s) available for morpholinoanthracycline mx2 and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Brain Neoplasms; Carubicin; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local | 1999 |
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Carubicin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis | 1999 |